Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Chronic Obstructive Pulmonary Disease Interventions:   Drug: SAR440340;   Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care;   Drug: Placebo;   Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care;   Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care Sponsors:   Sanofi;   Regeneron Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials